SynBioBeta Speaker
Matt Anderson-Baron
Future Fields
CEO
Dr. Matt Anderson-Baron is the cofounder and CEO of Future Fields, an Edmonton-based biomanufacturing company that is redefining the production of recombinant proteins. Matt is the inventor of Future Fields pioneering technology, the EntoEngine™, the world’s first synthetic biology platform to utilize the common fruit fly (Drosophila melanogaster) as a sustainable, scalable alternative to traditional bioreactors.Driven by the mission to "make the unmakeable," Matt has been instrumental in transitioning Future Fields from a bold startup concept into a global biomanufacturing partner. The company now works with industry leaders across life sciences, agrisciences, and drug discovery by manufacturing proteins at scale with a fraction of the environmental footprint and cost associated with conventional methods.Matt is A PhD-trained cell biologist turned entrepreneur, and combines a deep scientific rigor with a passion for disruptive technology. Formerly a touring punk-rock musician before returning to academia, he leverages his unique background to foster a culture of curiosity with candor and innovation.Future Fields is committed to the sustainable biotech, as a Green-certified lab, and as members of 1% for the Planet and the UN Global Compact.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Matt
This Year
•
-
TBD
Lighting Talk Brought to you By Future Fields
Get a Ticket
•
-
TBD
Lighting Talk Brought to you By Future Fields
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
